Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and very severe COPD.

LABAs aren't used alone, though. They come in combination medications that also include an inhaled corticosteroid (ICS). In ...

Long-acting beta-agonists (LABAs) are inhaled medications that open the airways, acting as bronchodilators. They are preferred when inhaled steroids do not adequately control symptoms. LABAs are ...

Inhaled steroids reduce and prevent inflammation, swelling, and mucus build-up in your airways and lungs to help prevent asthma attacks and help you breathe easier. But not everyone with asthma ...

Long-acting β 2 Agonists. Current benefits from inhaled LABA such as salmeterol and formoterol in the treatment of asthma continue to outweigh risks, which include a FDA 'black box' warning ...

Fatalities have been reported with excessive use of inhaled sympathomimetic drugs. Patients using Advair HFA should not use another medicine containing a LABA (eg, salmeterol, formoterol fumarate ...

LABA as monotherapy (without ICS ... Prescribe a short-acting inhaled β 2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Monitor for signs/symptoms ...

entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and an inhaled corticosteroid (LABA+LAMA+ICS) in instances when LABA+ICS dual therapy had ...

Participants used either montelukast or a LABA, which was considered "a more suitable active comparator than ICS because, like montelukast, it is an add-on drug; a majority of patients have ...